DaVita (DVA) Q3 2026 Earnings Call Transcript
DaVita (DVA) reported Q3 2026 adjusted operating income of $561M and EPS of $3.82. The company highlighted clinical advancements in fluid management and expanded HD dialyzers, expecting a national rollout by November. DaVita raised its Integrated Kidney Care (IKC) guidance to $65M for 2026, citing improved savings rates and partnerships. Full-year 2026 adjusted operating income is projected to be $2.175B-$2.25B, with EPS between $14.30-$15.20.
How this was made
The 30-second read
Why it matters
The most tradable items are the narrowed 2026 guidance ranges and the explicit IKC adjusted operating income expectation increase, plus the stated timing that positive volume growth effects begin in the back half of 2028. CMS policy updates (ESRD final rule) add a reimbursement-policy backdrop that can influence dialysis bundle economics.
Market read
Guidance narrowing and IKC income uplift are likely to drive positioning, while the longer-dated volume-growth timing and near-term tech cost drag may limit upside.
What to watch
The call emphasizes clinical outcomes (mortality, fluid management, expanded HD pilots) but the near-term financial impact is framed as no material adjusted operating income impact for 2026-2027, which could temper enthusiasm despite strong pilot adoption.
Background
DaVita’s Q3 2026 call highlights clinical initiatives (fluid management, expanded HD dialyzers, clearance of middle molecules) and operational readiness for a national rollout, alongside updates to Integrated Kidney Care (IKC) economics and U.S. dialysis cost pressures.
Ticker impact
DaVita guided full-year 2026 adjusted operating income to $2.175B-$2.25B and EPS to $14.30-$15.20, citing higher IKC and higher U.S. dialysis technology costs.
Likely modest upside bias if investors focus on IKC guidance raise and mortality/volume outlook, partially offset by concerns about higher U.S. dialysis costs and tech investment drag.
The article contains explicit, company-specific guidance ranges and a stated offset (IKC increase vs higher U.S. dialysis costs), which directly informs near-term earnings expectations and risk.
Market effects
Dialysis-provider peers may see read-across on reimbursement bundle dynamics (phosphate binders in the dialysis bundle) and on operational readiness for expanded HD adoption.
No clear regional market-specific impact beyond U.S. dialysis operations and CMS policy.
Limited, as the disclosures are U.S.-focused (CMS ESRD final rule, IKC Medicare Advantage economics).
Counterpoint
Investors may discount the long-dated back-half 2028 volume benefit and focus on near-term cost pressure from higher technology investments, treating the guidance narrowing as more about offsetting drags than accelerating growth.
Key entities
- companyDaVita
Provided Q3 results and narrowed full-year 2026 guidance, with IKC outperformance offset by higher U.S. dialysis technology investments.
- regulatorCMS
Released the ESRD final rule confirming permanent incorporation of phosphate binders into the dialysis bundle and setting a headline rate increase for large dialysis organizations.
- governmentHHS
Released the Kidney Care National Plan referenced as aligning with administration goals.
- partnerHumana
Announced as part of an IKC upstream care expansion to approximately 10,000 chronic kidney disease patients.
